Elizabeth,
Don't pay too much attention to comments by people that have a short position and want the longs to "see the light" & sell their shares so they are able to cover.
They got a little scared 3 weeks ago when INGN announced that half of patients with advanced small cell lung cancer responded to its INGN 225 molecular cancer vaccine in combination with subsequent chemotherapy.
As you may recall, that announcement was after the prior week they had mentioned that a combination of INGN 241 and Avastin may be much more effective in treating lung cancer than Avastin alone, since treatment with Avastin alone showed only minor tumor regression and no animals were cured of their cancer, but when INGN 241 was added,a complete inhibitory activity was accomplished.
In the last week in January, it also commented about the previous reports that ADVEXIN's tumor responses and median survival are comparable to results obtained with other more toxic therapies in recurrent head and neck cancer patients & that the "biomarker data" improves upon those results by identifying the patients most likely to benefit from ADVEXIN treatment, with even greater increase in survival and tumor growth control.
That "biomarker data", which was noticed when analyzing the latest trial results is what Adam Feurestein tried to deride in his sneering, lampooning tirade in which he claimed it had about the same value as if left handed patients had shown a better response.
Today, Marek Fuchs at the Street.com is coming out with an article trying to see if it can reinforce A.F's action for the shorts, which seems to be running out of steam.<g>
The stock has shown some intraday resilience at the 4.60 level in spite of the general market & Fuchs article.That is where the nearest intraday support seems to be at present with resistance at the 4.70 level.
I was hopeful that with the help of F.& F. we could be able to pick up some shares around the 4.30 level, but it seems that they will have to come out with a couple of follow up articles or the general market slide more before the ASCO meeting, which this Yr. is coming out a little later than usual.<g>
RAGL
Bernard |
